Emine Cesmecioglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emine Cesmecioglu has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Yukako Yagi
Department of Pathology & Lab Medicine Memorial Sloan Kettering Cancer Center New York City New York USA
3 shared publications - Alexei Teplov
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
2 shared publications - Efsevia Vakiani
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
2 shared publications - Huseyin Kemal Turkoz
Department of Internal Medicine, Department of Pathology, Marmara University Faculty of Medicine, Istanbul, Türkiye
2 shared publications - Jinru Shia
Memorial Sloan Kettering Cancer Center
2 shared publications - Julio Garcia-Aguilar
Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
2 shared publications
Latest Publications
- 25 October 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (11) , 295
Safety, tissue adequacy, and diagnostic contribution of ultrasound-guided synovial biopsy: a retrospective multicenter observational study in a heterogeneous rheumatology cohort
To evaluate procedural safety as the primary outcome of ultrasound-guided synovial biopsy (UGSB) in a real-world, multicenter rheumatology setting. Secondary outcomes included technical tissue adequacy, histopathological yield, patient-reported outcomes, willingness to undergo repeat biopsy, clinical indications, and diagnostic contribution. This retrospective multicenter observational study included 87 patients who underwent UGSB for diagnostic or clinical indications. Demographic and clinical data, indication, biopsied joint, ultrasonographic findings, adverse events, and patient-reported outcomes using a Visual Analogue Scale (VAS 0–10) for pain, swelling, and limitation of motion were collected pre- and post-procedure. Adverse events and willingness to undergo repeat biopsy were recorded. Diagnoses were classified as rheumatoid arthritis (RA), undifferentiated arthritis, or other rheumatologic diseases. Of the 87 patients (57.5% female; median age 46 years, IQR 17), 47.1% were diagnosed with RA, 31.0% had undifferentiated arthritis, and 21.8% had other rheumatologic conditions. The knee was the most frequently biopsied joint (69.0%). Ultrasonographic grade ≥ 2 synovitis was detected in 83.3% and power Doppler signal in 33.3% of the 54 patients with available US data. Adequate synovial tissue for histopathological evaluation was obtained in 90% of procedures. Post-procedural VAS scores demonstrated significant reductions in pain, swelling, and limitation of motion compared with pre-biopsy assessments (p < 0.001 for all). Ultrasonographic synovitis severity correlated with the histological Krenn synovitis score (greyscale ρ = 0.31, p = 0.036; effusion ρ = 0.48, p = 0.001). Adverse events were infrequent and predominantly mild; transient pain was the most common complication (19.5%). Sensory impairment and vasovagal reactions each occurred in one patient (1.1%). No tendon, vascular, ligament, or muscle injury, hemarthrosis, infection, or thromboembolic complications were observed. Sixty-seven patients (77.0%) reported willingness to undergo repeat biopsy if clinically indicated. Following completion of the overall diagnostic work-up—integrating clinical, laboratory, imaging, microbiological, and histopathological findings—the proportion classified as having undifferentiated arthritis decreased from 31.0% to 13.8%. UGSB is a safe, feasible, and well-tolerated minimally invasive procedure with high patient acceptability and a high rate of adequate tissue acquisition across a broad spectrum of rheumatologic diseases. In selected patients with diagnostically challenging arthritis, synovial tissue analysis may provide histopathological or microbiological information that contributes to diagnostic clarification when integrated with the broader clinical work-up. These findings support the feasibility of UGSB in appropriately selected clinical settings and provide a basis for future prospective studies with standardized protocols.
- 25 October 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (11) , 295
Safety, tissue adequacy, and diagnostic contribution of ultrasound-guided synovial biopsy: a retrospective multicenter observational study in a heterogeneous rheumatology cohort
To evaluate procedural safety as the primary outcome of ultrasound-guided synovial biopsy (UGSB) in a real-world, multicenter rheumatology setting. Secondary outcomes included technical tissue adequacy, histopathological yield, patient-reported outcomes, willingness to undergo repeat biopsy, clinical indications, and diagnostic contribution. This retrospective multicenter observational study included 87 patients who underwent UGSB for diagnostic or clinical indications. Demographic and clinical data, indication, biopsied joint, ultrasonographic findings, adverse events, and patient-reported outcomes using a Visual Analogue Scale (VAS 0–10) for pain, swelling, and limitation of motion were collected pre- and post-procedure. Adverse events and willingness to undergo repeat biopsy were recorded. Diagnoses were classified as rheumatoid arthritis (RA), undifferentiated arthritis, or other rheumatologic diseases. Of the 87 patients (57.5% female; median age 46 years, IQR 17), 47.1% were diagnosed with RA, 31.0% had undifferentiated arthritis, and 21.8% had other rheumatologic conditions. The knee was the most frequently biopsied joint (69.0%). Ultrasonographic grade ≥ 2 synovitis was detected in 83.3% and power Doppler signal in 33.3% of the 54 patients with available US data. Adequate synovial tissue for histopathological evaluation was obtained in 90% of procedures. Post-procedural VAS scores demonstrated significant reductions in pain, swelling, and limitation of motion compared with pre-biopsy assessments (p < 0.001 for all). Ultrasonographic synovitis severity correlated with the histological Krenn synovitis score (greyscale ρ = 0.31, p = 0.036; effusion ρ = 0.48, p = 0.001). Adverse events were infrequent and predominantly mild; transient pain was the most common complication (19.5%). Sensory impairment and vasovagal reactions each occurred in one patient (1.1%). No tendon, vascular, ligament, or muscle injury, hemarthrosis, infection, or thromboembolic complications were observed. Sixty-seven patients (77.0%) reported willingness to undergo repeat biopsy if clinically indicated. Following completion of the overall diagnostic work-up—integrating clinical, laboratory, imaging, microbiological, and histopathological findings—the proportion classified as having undifferentiated arthritis decreased from 31.0% to 13.8%. UGSB is a safe, feasible, and well-tolerated minimally invasive procedure with high patient acceptability and a high rate of adequate tissue acquisition across a broad spectrum of rheumatologic diseases. In selected patients with diagnostically challenging arthritis, synovial tissue analysis may provide histopathological or microbiological information that contributes to diagnostic clarification when integrated with the broader clinical work-up. These findings support the feasibility of UGSB in appropriately selected clinical settings and provide a basis for future prospective studies with standardized protocols.
- 16 September 2026
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 34 (6) , 372-378
PRAME as a Diagnostic Adjunct in Clear Cell Sarcoma
Clear cell sarcoma (CCS) is a rare soft tissue neoplasm characterized by melanocytic differentiation and recurrent EWSR1 rearrangements. Owing to its overlapping morphology and immunophenotype with malignant melanoma (MM), distinction between these entities can be challenging, particularly in small biopsies or metastatic settings. Preferentially Expressed Antigen in Melanoma (PRAME) has emerged as a valuable marker in melanocytic pathology; however, its utility in CCS remains to be fully elucidated. We conducted a retrospective analysis of 26 CCS cases from 2 sarcoma referral centers, assessing PRAME immunohistochemistry (IHC) alongside a validation cohort of 120 cutaneous melanomas. Clinicopathologic features, EWSR1 rearrangement status, and survival data were reviewed. The patient cohort (65.4% female) had a mean age of 36.1±15.4 years, with most tumors arising in the extremities. The mean tumor diameter was 4.9±2.8 cm. PRAME was negative in 25/26 (96.2%) CCS cases, with only one case showing focal weak staining. Nineteen CCS cases demonstrated EWSR1 gene rearrangement on molecular analysis. In contrast, PRAME was positive in 110/120 melanomas (91.7%), displaying diffuse (80%) or focal (11.7%) staining. Our findings indicate that PRAME is almost uniformly absent in CCS, in sharp contrast to its strong and prevalent expression in melanoma. PRAME immunohistochemistry may therefore serve as a useful and cost-effective adjunct in the differential diagnosis of melanocytic soft tissue tumors. In an appropriate morphologic and clinical context, the absence of PRAME expression supports a diagnosis of CCS over melanoma, particularly when molecular confirmation of EWSR1 rearrangement is unavailable or inconclusive.
- 16 September 2026
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 34 (6) , 372-378
PRAME as a Diagnostic Adjunct in Clear Cell Sarcoma
Clear cell sarcoma (CCS) is a rare soft tissue neoplasm characterized by melanocytic differentiation and recurrent EWSR1 rearrangements. Owing to its overlapping morphology and immunophenotype with malignant melanoma (MM), distinction between these entities can be challenging, particularly in small biopsies or metastatic settings. Preferentially Expressed Antigen in Melanoma (PRAME) has emerged as a valuable marker in melanocytic pathology; however, its utility in CCS remains to be fully elucidated. We conducted a retrospective analysis of 26 CCS cases from 2 sarcoma referral centers, assessing PRAME immunohistochemistry (IHC) alongside a validation cohort of 120 cutaneous melanomas. Clinicopathologic features, EWSR1 rearrangement status, and survival data were reviewed. The patient cohort (65.4% female) had a mean age of 36.1±15.4 years, with most tumors arising in the extremities. The mean tumor diameter was 4.9±2.8 cm. PRAME was negative in 25/26 (96.2%) CCS cases, with only one case showing focal weak staining. Nineteen CCS cases demonstrated EWSR1 gene rearrangement on molecular analysis. In contrast, PRAME was positive in 110/120 melanomas (91.7%), displaying diffuse (80%) or focal (11.7%) staining. Our findings indicate that PRAME is almost uniformly absent in CCS, in sharp contrast to its strong and prevalent expression in melanoma. PRAME immunohistochemistry may therefore serve as a useful and cost-effective adjunct in the differential diagnosis of melanocytic soft tissue tumors. In an appropriate morphologic and clinical context, the absence of PRAME expression supports a diagnosis of CCS over melanoma, particularly when molecular confirmation of EWSR1 rearrangement is unavailable or inconclusive.
- Open Access
- 26 May 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (6) , 569
Optimization of Scanning Protocol for AI-Integrated Assessment of HER2 Dual Bright-Field In-Situ Hybridization Application in Breast Cancer
Accurately determining HER2 status is essential for breast cancer treatment. We developed an AI-integrated in-house application for automated Dual bright-field (BF) in situ hybridization (ISH) analysis on whole slide images (WSIs), although optimal scanning conditions remain unclear. We evaluated scanners and optimized scanning protocols for clinical application. Ten de-identified invasive breast carcinoma cases, with HER2 immunohistochemistry and FISH results, were analyzed using three scanners and six scanning protocols. WSIs scanned by Scanner ‘A’ have 0.12 µm/pixel with 0.95 NA (A1) and 1.2 NA (A2); Scanner ‘B’ have 0.08 µm/pixel (B1); 0.17 µm/pixel (B2); and 0.17 µm/pixel with extended focus (1.4 µm step size and three layers) (B3); Scanner ‘C’ has 0.26 µm/pixel (C1) resolution. Results showed scanning protocols A1, A2, B2, and B3 yielded HER2 gene amplification status and ASCO/CAP ISH group results consistent with manual FISH as the ground truth. However, protocol C demonstrated poor concordance due to nuclei detection failure in six cases. The AI-integrated application achieved the best performance using scanning protocols with optimized resolutions of 0.12 µm/pixel and 0.17 µm/pixel with extended focus. This study highlights the importance of scanner selection in AI-based HER2 assessment and demonstrates that optimized scanning parameters enhance the accuracy and reliability of automated Dual BF ISH analysis.
- 26 May 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (6) , 569
Open AccessOptimization of Scanning Protocol for AI-Integrated Assessment of HER2 Dual Bright-Field In-Situ Hybridization Application in Breast Cancer
Accurately determining HER2 status is essential for breast cancer treatment. We developed an AI-integrated in-house application for automated Dual bright-field (BF) in situ hybridization (ISH) analysis on whole slide images (WSIs), although optimal scanning conditions remain unclear. We evaluated scanners and optimized scanning protocols for clinical application. Ten de-identified invasive breast carcinoma cases, with HER2 immunohistochemistry and FISH results, were analyzed using three scanners and six scanning protocols. WSIs scanned by Scanner ‘A’ have 0.12 µm/pixel with 0.95 NA (A1) and 1.2 NA (A2); Scanner ‘B’ have 0.08 µm/pixel (B1); 0.17 µm/pixel (B2); and 0.17 µm/pixel with extended focus (1.4 µm step size and three layers) (B3); Scanner ‘C’ has 0.26 µm/pixel (C1) resolution. Results showed scanning protocols A1, A2, B2, and B3 yielded HER2 gene amplification status and ASCO/CAP ISH group results consistent with manual FISH as the ground truth. However, protocol C demonstrated poor concordance due to nuclei detection failure in six cases. The AI-integrated application achieved the best performance using scanning protocols with optimized resolutions of 0.12 µm/pixel and 0.17 µm/pixel with extended focus. This study highlights the importance of scanner selection in AI-based HER2 assessment and demonstrates that optimized scanning parameters enhance the accuracy and reliability of automated Dual BF ISH analysis.
- Open Access
- 6 August 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (16) , 1704
Micro-Computed Tomography Whole-Block Imaging Reveals Origin and Path of Rectal Cancer Tumor Deposits: A Pilot Study
In colorectal carcinoma (CRC), tumor deposits (TDs) are described as macroscopic/microscopic nests/nodules in the lymph drainage area discontinuous with the primary mass, without identifiable lymph node (LN) tissue, and not confined to vascular or perineural spaces. A TD is categorized as pN1C only when no bona fide LN metastasis exists. However, there has been an ongoing debate on whether TDs should be counted as LNs. The fact that the origin of TDs is not fully understood adds further uncertainty. This pilot study aims to evaluate whether whole-block imaging by micro-computed tomography (micro-CT WBI) that enables three-dimensional reconstruction of whole-mount (WM) blocks can serve as a tool to assess the origin and path of CRC TDs. We evaluated whole-slide imaging (WSI) and micro-CT WBI of 20 WM blocks from a rectal cancer resection that contained TDs. Each TD was tracked through the contiguous blocks to define their origin and path. Of eleven TDs identified on WSI, six were detected on WBI. Strikingly, six of six TDs trackable through the blocks on WBI revealed an origin from the main tumor. This pilot study provided evidence that micro-CT WBI can serve as an effective tool to evaluate the origin and path of CRC TDs.
- 6 August 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (16) , 1704
Open AccessMicro-Computed Tomography Whole-Block Imaging Reveals Origin and Path of Rectal Cancer Tumor Deposits: A Pilot Study
In colorectal carcinoma (CRC), tumor deposits (TDs) are described as macroscopic/microscopic nests/nodules in the lymph drainage area discontinuous with the primary mass, without identifiable lymph node (LN) tissue, and not confined to vascular or perineural spaces. A TD is categorized as pN1C only when no bona fide LN metastasis exists. However, there has been an ongoing debate on whether TDs should be counted as LNs. The fact that the origin of TDs is not fully understood adds further uncertainty. This pilot study aims to evaluate whether whole-block imaging by micro-computed tomography (micro-CT WBI) that enables three-dimensional reconstruction of whole-mount (WM) blocks can serve as a tool to assess the origin and path of CRC TDs. We evaluated whole-slide imaging (WSI) and micro-CT WBI of 20 WM blocks from a rectal cancer resection that contained TDs. Each TD was tracked through the contiguous blocks to define their origin and path. Of eleven TDs identified on WSI, six were detected on WBI. Strikingly, six of six TDs trackable through the blocks on WBI revealed an origin from the main tumor. This pilot study provided evidence that micro-CT WBI can serve as an effective tool to evaluate the origin and path of CRC TDs.
- Open Access
- 8 April 2024
- Published by Springer Nature in Cureus
- Vol. 16 (4)
Comparison of Microsatellite Instability With Clinicopathologic Data in Patients With Colon Adenocarcinoma
Background Microsatellite instability (MSI) is a genetic condition caused by errors in DNA repair genes that cause colorectal cancer (CRC). The literature contradicts the frequency of MSI in sporadic CRCs and its effect on prognosis. This study investigated the distribution of clinicopathologic features and the relationship between MSI and survival outcomes. Methodology This is a retrospective study of 101 consecutive cases of CRC and immunohistochemical studies. All cases were retrospectively reviewed and reevaluated by histological grade, lymphovascular invasion, perineural invasion, tumor borders, dirty necrosis, tumor-infiltrating lymphocytes (TILs), Crohn’s-like lymphoid reaction, mucinous and medullary differentiation, and tumoral budding from pathological slides. An immunohistochemical study was performed in appropriate blocks for using MLH-1, MSH-2, MSH-6, and PMS-2. We collected the clinical stage, pathological tumor stage, lymph node metastasis, age, sex, tumor diameter, distant metastasis, localization, and survival information from patients’ clinical data. Results There was no statistically significant difference between the two groups regarding age, gender, tumor diameter, histological grade, tumor border, dirty necrosis, TILs, N and M stage, perineural and lymphovascular invasion, mucinous differentiation, medullary differentiation, and tumor budding characteristics of the patients. The MSI-H group was more frequently located in the right colon and transverse colon (p < 0.001), and the T stage was higher among them than in the MSI-L group (p = 0.014). Upon multivariate regression analysis, MSI status had no significant effect on survival time. Age and stage N and M were independent prognostic factors for colon cancer prognosis. Conclusions Our study presented the distribution of clinicopathological features and their relationship with MSI for 101 regional CRC patients. MSI status was detected by immunohistochemistry. Identifying MSI in CRCs may help personalize therapy planning. As the distribution of the features may vary from population to population, further investigations are needed on this topic.
- 8 April 2024
- Published by Springer Nature in Cureus
- Vol. 16 (4)
Open AccessComparison of Microsatellite Instability With Clinicopathologic Data in Patients With Colon Adenocarcinoma
Background Microsatellite instability (MSI) is a genetic condition caused by errors in DNA repair genes that cause colorectal cancer (CRC). The literature contradicts the frequency of MSI in sporadic CRCs and its effect on prognosis. This study investigated the distribution of clinicopathologic features and the relationship between MSI and survival outcomes. Methodology This is a retrospective study of 101 consecutive cases of CRC and immunohistochemical studies. All cases were retrospectively reviewed and reevaluated by histological grade, lymphovascular invasion, perineural invasion, tumor borders, dirty necrosis, tumor-infiltrating lymphocytes (TILs), Crohn’s-like lymphoid reaction, mucinous and medullary differentiation, and tumoral budding from pathological slides. An immunohistochemical study was performed in appropriate blocks for using MLH-1, MSH-2, MSH-6, and PMS-2. We collected the clinical stage, pathological tumor stage, lymph node metastasis, age, sex, tumor diameter, distant metastasis, localization, and survival information from patients’ clinical data. Results There was no statistically significant difference between the two groups regarding age, gender, tumor diameter, histological grade, tumor border, dirty necrosis, TILs, N and M stage, perineural and lymphovascular invasion, mucinous differentiation, medullary differentiation, and tumor budding characteristics of the patients. The MSI-H group was more frequently located in the right colon and transverse colon (p < 0.001), and the T stage was higher among them than in the MSI-L group (p = 0.014). Upon multivariate regression analysis, MSI status had no significant effect on survival time. Age and stage N and M were independent prognostic factors for colon cancer prognosis. Conclusions Our study presented the distribution of clinicopathological features and their relationship with MSI for 101 regional CRC patients. MSI status was detected by immunohistochemistry. Identifying MSI in CRCs may help personalize therapy planning. As the distribution of the features may vary from population to population, further investigations are needed on this topic.
- Open Access
- 14 April 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (4) , 984
Pathological Evaluation of Rectal Cancer Specimens Using Micro-Computed Tomography
Whole-block imaging (WBI) using micro-computed tomography (micro-CT) allows the nondestructive reconstruction of a three-dimensional view of tissues, implying that WBI may be used for accurate pathological evaluation of patients with rectal cancer. HOWEVER, the clinical impact of this approach is unclear. We aimed to clarify the efficacy of WBI in the whole-mount specimens of locally advanced rectal cancer. A total of 237 whole-mount formalin-fixed paraffin-embedded blocks from 13 patients with rectal cancer who underwent surgical treatment were enrolled and scanned with micro-CT to generate three-dimensional images. WBI was evaluated following the conventional pathological review of the corresponding whole-slide imaging (WSI). WBI identified all tumor sites detected using WSI. Furthermore, WBI revealed one additional tumor site, which was not detected using WSI. Tumor resection margin was significantly closer to the soft-tissue edge when measured using WBI (7.7 mm vs. 6.6 mm, p < 0.01). Seventy-six percent of tumor deposits on WSI were changed according to the evidence of tumor interaction with the surrounding tissues confirmed using WBI. Furthermore, WBI revealed 25 additional lymph nodes, six of which were metastatic. The combination of conventional hematoxylin and eosin-stained imaging and WBI may contribute to an accurate pathological assessment.
- 14 April 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (4) , 984
Open AccessPathological Evaluation of Rectal Cancer Specimens Using Micro-Computed Tomography
Whole-block imaging (WBI) using micro-computed tomography (micro-CT) allows the nondestructive reconstruction of a three-dimensional view of tissues, implying that WBI may be used for accurate pathological evaluation of patients with rectal cancer. HOWEVER, the clinical impact of this approach is unclear. We aimed to clarify the efficacy of WBI in the whole-mount specimens of locally advanced rectal cancer. A total of 237 whole-mount formalin-fixed paraffin-embedded blocks from 13 patients with rectal cancer who underwent surgical treatment were enrolled and scanned with micro-CT to generate three-dimensional images. WBI was evaluated following the conventional pathological review of the corresponding whole-slide imaging (WSI). WBI identified all tumor sites detected using WSI. Furthermore, WBI revealed one additional tumor site, which was not detected using WSI. Tumor resection margin was significantly closer to the soft-tissue edge when measured using WBI (7.7 mm vs. 6.6 mm, p < 0.01). Seventy-six percent of tumor deposits on WSI were changed according to the evidence of tumor interaction with the surrounding tissues confirmed using WBI. Furthermore, WBI revealed 25 additional lymph nodes, six of which were metastatic. The combination of conventional hematoxylin and eosin-stained imaging and WBI may contribute to an accurate pathological assessment.